title: [Erythropoietin through the placenta barrier and fetal blood-brain barrier with transient uteroplacental ischemia].
abstract: OBJECTIVE
  To observe the permeability of recombinant human erythropoietin through placenta barrier and fetal blood-brain barrier after transient uteroplacental ischemia.
  
  
  METHODS
  Rats on days 19 of pregnancy were divided into rhEPO treated group, ischemia-reperfusion group and sham operated group. Fetal ischemia in rhEPO treated group and ischemia-reperfusion group was induced by bilateral occlusion of the utero-ovarian artery for 20 minutes. Different dosage of 125I-rhEPO (2500 U/kg, 5000 U/kg, 7500 U/kg) was injected into the rats through caudal veins 30 min before injury in rhEPO treated group and sham-operated group. Saline was administered intravenously 30 min before the induction of hypoxic-ischemic injury in ischemia-reperfusion group. The amniotic fluid, placenta and fetal organs including brain, liver, heart, lung and kidney were collected to measure the radioactivity at 24h after injury.
  
  
  RESULTS
  125I-rhEPO was detected in amniotic fluid, placenta and fetal organs. The radioactivity of 125I-rhEPO in these tissues increased gradually with the increased dose injected in rhEPO treated group and sham-operated group. There were significant differences in the radioactivity of 125I-rhEPO between rhEPO treated group and sham-operated group (P < 0.05).
  
  
  CONCLUSIONS
  The permeability of rhEPO through placental barrier and blood-brain barrier increased under the condition of fetal ischemia and hypoxia.
authors.affiliation: Department of Anesthesia, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yu-Shan
authors.initials: YS
authors.lastname: Ma
authors.forename: Jun
authors.initials: J
authors.lastname: Zhou
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Yu
authors.initials: Y
authors.lastname: Du
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Lin
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D004921:Erythropoietin / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D005311:Fetal Hypoxia / Q000188:drug therapy*; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D010539:Permeability; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000188:drug therapy
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin